| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-388
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-327 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate |
2020-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49b26ba760f1bb30dd2535bf94f9d937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e7506cbe34de0ce9e3f7881de9ea203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4e00f4d67659fd9ee08b7520cba79c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08f49a7990c9122320108bd863cbc6a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a3fcfc45474b870e3823457363ed491 |
| publicationDate |
2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3916001-A1 |
| titleOfInvention |
Method for antibody purification including step where activated carbon material is used |
| abstract |
To provide a method for purifying an antibody to a sufficient degree of purity for therapeutic use in humans by removing impurities contained in a solution efficiently while reducing production cost and the purification period in the purification of the antibody. It was found that an antibody can be reliably purified to a high degree of purity by an activated carbon material, regardless of the amounts or species of impurities co-present, and that high viral clearance can be attained reliably. Based on the finding, a treatment with an activated carbon material could be used in place of AEX chromatography achieving viral clearance in a step of purifying a therapeutic antibody using CHO cells. As a result, an antibody can be simply and effectively purified to a sufficient degree of purity for therapeutic use in humans compared to a conventional purification method, while reducing production cost. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023180523-A1 |
| priorityDate |
2019-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |